Duloxetine for Major Depression in Peri-/Postmenopausal Women

Phase 4 Unknown 70 enrolled Hamilton Health Sciences Corporation Eli Lilly and Company · collab McMaster University · collab St. Joseph's Healthcare Hamilton · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to characterize a range of brain activation symptoms associated with major depression in peri- and post-menopausal women. Also, assessing brain activation before and after the treatment might help to uncover some mechanisms associated with the pathophysiology of depression and menopause.

Timeline

Start: 2009-05
Primary completion: 2012-02
Completion: 2012-06

Publications

Results Frey BN, Hall GB, Attard S, Yucel K, Skelin I, Steiner M, Soares CN. Shift in the brain network of emotional regulation in midlife women: is the menopausal transition the turning point? Menopause. 2010 Jul;17(4):840-5. doi: 10.1097/gme.0b013e3181df840f.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Duloxetine	Small molecule	60 mg	—
Subject	Duloxetine	Small molecule	120 mg	—

Duloxetine for Major Depression in Peri-/Postmenopausal Women

Summary

Timeline

Publications

Drugs

Indications